

# ICCR's Best Practices for Promoting Next-Generation Risk Assessment of Cosmetic Ingredients

Matt Dent

19 February 2026

**SERS**  
Safety, Environmental  
& Regulatory Science



# Talk Outline

- The ICCR and the Principles of NGRA
- Applying the Principles to Case Studies
- Developing Best Practice
- What Next?



## The ICCR

The International Cooperation on Cosmetics Regulation is a voluntary international group of cosmetics regulatory authorities from Brazil, Canada, Chinese Taipei, the European Union, Israel, Japan, Republic of Korea, and the United States who meet on an annual basis to discuss cosmetics safety and regulation, as well as enter into a constructive dialogue with relevant cosmetics industry trade associations.

<https://www.iccr-cosmetics.org>

# ICCR Work Products

The experts that participate in the ICCR have produced:

- White papers that provide a background on the current status across jurisdictions on a given matter or approach
- General principles that should be considered in addressing a particular regulatory issue in a manner that is specific to cosmetic products
- Recommendations on specific regulatory/safety issues that can include definitions, acceptable levels, methodologies, endorsement of other international standards as applicable to cosmetic products, etc.

<https://www.iccr-cosmetics.org>



# Development of the Principles

## 2016

The ICCR approached Cosmetics Europe to ask for help in defining a way to integrate non-animal test data for cosmetic ingredient safety assessment

→ “Integrated Strategies” Joint Regulator-Industry Working Group formed



## 2016-2017

The Joint Working Group agreed that to build on a solid foundation, we would first define the Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients



## 2018

The “ICCR Principles of NGRA” were published in Computational Toxicology

<https://doi.org/10.1016/j.comtox.2018.06.001>



Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients

Matthew Dent<sup>a,c</sup>, Renata Teixeira Amaral<sup>b</sup>, Pedro Amores Da Silva<sup>b</sup>, Jay Ansell<sup>c</sup>, Fanny Boisleve<sup>d</sup>, Masato Hatao<sup>e</sup>, Akihiko Hirose<sup>f</sup>, Yutaka Kasai<sup>g</sup>, Petra Kern<sup>h</sup>, Reinhard Kreiling<sup>i</sup>, Stanley Milstein<sup>j</sup>, Beta Montemayor<sup>k</sup>, Julcemara Oliveira<sup>l</sup>, Andrea Richarz<sup>m</sup>, Rob Taalman<sup>n</sup>, Eric Vaillancourt<sup>o</sup>, Rajeshwar Verma<sup>p</sup>, Nashira Vieira O'Reilly Cabral Posada<sup>q</sup>, Craig Weiss<sup>r</sup>, Hajime Kojima<sup>s</sup>

<sup>a</sup> Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, UK  
<sup>b</sup> ABIPPEC - Association of the Cosmetic, Toiletry and Fragrance Industry (ABIPPEC), Av. Paulista, 1313 Conquista Clara, São Paulo, SP 01311-000, Brazil  
<sup>c</sup> US Personal Care Products Council (PCPC), 1600 L St. NW, Suite 1200, Washington, D.C. 20036, USA  
<sup>d</sup> Johnson & Johnson Santé Beauté France, Domaines de Maitremont, CS 10615, F-27106 VAL DE REUIL, Cedex, France  
<sup>e</sup> Japan Cosmetic Industry Association (JCIA), Metro City Kamayacho 6F, 5-1-5, Tamaocho, Minato-ku, Tokyo 105-0001 Japan  
<sup>f</sup> National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, 158-8501 Tokyo, Japan  
<sup>g</sup> Kan Corporation, External Relations & Government Affairs 2-1-3, Benka, Saitama-Ku, Tokyo 131-8501 Japan  
<sup>h</sup> Procter and Gamble Service Company NY, Temulaan 100, B-1853 Stranbeek River, Belgium  
<sup>i</sup> Claranset Produkte (CE) GmbH, Global Toxicology and Immunology, Am Unioy Park 1, 65843 Sulzbach, Germany  
<sup>j</sup> US Food and Drug Administration (US FDA), Office of Cosmetics and Colors (OCCAC), Center for Food Safety and Applied Nutrition (CFSAN), 5001 Campus Drive, College Park, MD 20740, USA  
<sup>k</sup> Cosmetics Alliance Canada, 420 Britannia Road East Suite 102, Mississauga, ON L4Z 3E5, Canada  
<sup>l</sup> Brazilian Health Regulatory Agency (ANVISA), Gerência de Produtos de Higiene, Perfumes, Cosméticos e Saneantes, SIA Trecho 5, lote 200, Area Especial 57 - CEP 71205-050, Brazil  
<sup>m</sup> European Commission, Joint Research Centre (JRC), Directorate for Health, Consumers and Reference Materials, Chemical Safety and Alternative Methods Unit, Via E. Fermi 2749, 21027 Arpa, VA, Italy  
<sup>n</sup> Cosmetics Europe, Avenue Herrmann-Dubrova 40, 1160 Anderlecht, Belgium  
<sup>o</sup> Health Canada (HC), Consumer Product Safety Directorate, Healthy Environments and Consumer Safety Branch, 269 Laurier Ave. W., Ottawa, ON K1A 0K9, Canada  
<sup>p</sup> Independent Cosmetics Manufacturing and Distributors (ICMDA), 21922 Field Parkway, Suite 2015, Deer Park, IL 60010, USA

## 4 Main overriding principles:

- The overall goal is a human safety risk assessment
- The assessment is exposure led
- The assessment is hypothesis driven
- The assessment is designed to prevent harm

## 3 Principles describe how a NGRA should be conducted:

- Following an appropriate appraisal of existing information
- Using a tiered and iterative approach
- Using robust and relevant methods and strategies

## 2 Principles for documenting NGRA:

- Sources of uncertainty should be characterized and documented
- The logic of the approach should be transparent and documented


# From Principles to Application

The Joint Working Group built on the foundations of the principles to describe the tools that may be useful in the risk assessment of cosmetic ingredients, and how they could be applied.

<https://www.iccr-cosmetics.org>



# The Seurat-1 workflow




Continue through tiers until there is sufficient information to make a decision: assessment may be complete at any tier  
 Berggren et al., (2017) *Computational Toxicology* 4: 31-44.  
<https://doi.org/10.1016/j.comttox.2017.10.001>

# Mapping different NAMs to the workflow

**TIER 0: IDENTIFY**  
USE SCENARIO,  
CHEMICAL OF CONCERN  
AND COLLECT EXISTING  
INFORMATION

**TIER 1: HYPOTHESIS**  
FORMULATION FOR AB  
INITIO APPROACH

**TIER 2:**  
APPLICATION OF AB  
INITIO APPROACH



- Read across
- Exposure-based waiving
- In silico* tools
- Metabolism and metabolite identification
- Physiologically-based kinetic modelling
- In chemico* assays
- 'Omics
- Reporter gene assays
- In vitro* pharmacological profiling
- 3D culture systems
- Organ-on-chip
- Pathways modelling
- Human studies

Key: Readiness judged by ICCR in 2018


<https://www.iccr-cosmetics.org/component/attachments/?task=download&id=85>

- Already in common use
- Mature with likely utility
- Insufficiently developed

**TIER 0: IDENTIFY**  
USE SCENARIO,  
CHEMICAL OF CONCERN  
AND COLLECT EXISTING  
INFORMATION

**TIER 1: HYPOTHESIS**  
FORMULATION FOR AB  
INITIO APPROACH

**TIER 2:**  
APPLICATION OF AB  
INITIO APPROACH



- Read across
- Exposure-based waiving
- In silico* tools
- Metabolism and metabolite identification
- Physiologically-based kinetic modelling
- In chemico* assays
- 'Omics
- Reporter gene assays
- In vitro* pharmacological profiling
- 3D culture systems
- Organ-on-chip
- Pathways modelling
- Human studies


# Workshop in Canada: 2019

Case studies play a pivotal role in assessing and applying new approaches


ICCR held a workshop to discuss the ability of NGRA to support robust decision making

Two systemic toxicity case studies that were “works in progress” were discussed: Coumarin ([Baltazar et al., 2020](#)) and Phenoxyethanol ([OECD 2021](#))

- What were the common tools?
- How were the ICCR Principles being applied?
- What was the decision output?



[Dent et al., 2021](#)



# Workshop in Canada: 2019

Case studies play a pivotal role in assessing and applying new approaches

ICCR held a workshop to discuss the ability of NGRA to support robust decision making

Two systemic toxicity case studies that were “works in progress” were discussed: Coumarin ([Baltazar et al., 2020](#)) and Phenoxyethanol ([OECD 2021](#))

- What were the common tools?
- How were the ICCR Principles being applied?
- What was the decision output?
  - **“Protection not Prediction”**

[Dent et al., 2021](#)

# Workshop Outputs: Jobs to be done

1. Increase confidence in exposure predictions (including metabolites)
2. Determine whether tools give us enough biological coverage
3. Be explicit about the level of confidence in the assessment
4. Develop agreed standards for using tools and reporting data
5. Distinguish between adaptation and adversity
6. Develop an updated risk assessment workflow
7. More case studies

Regulatory Toxicology and Pharmacology 125 (2021) 105026



Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients

M.P. Dent<sup>a,\*</sup>, E. Vaillancourt<sup>b</sup>, R.S. Thomas<sup>c</sup>, P.L. Carmichael<sup>a</sup>, G. Ouedraogo<sup>d</sup>, H. Kojima<sup>e</sup>, J. Barroso<sup>f</sup>, J. Ansell<sup>g</sup>, T.S. Barton-Maclaren<sup>b</sup>, S.H. Bennekou<sup>h</sup>, K. Boekelheide<sup>i</sup>, J. Ezendam<sup>j</sup>, J. Field<sup>b</sup>, S. Fitzpatrick<sup>k</sup>, M. Hatao<sup>l</sup>, R. Kreiling<sup>m</sup>, M. Lorencini<sup>n,1</sup>, C. Mahony<sup>o</sup>, B. Montemayor<sup>p</sup>, R. Mazaro-Costa<sup>q</sup>, J. Oliveira<sup>r</sup>, V. Rogiers<sup>s</sup>, D. Smegal<sup>k</sup>, R. Taalman<sup>t</sup>, Y. Tokura<sup>u</sup>, R. Verma<sup>k</sup>, C. Willett<sup>v</sup>, C. Yang<sup>w</sup>



# Workshop Outputs: Jobs to be done

1. Increase **confidence** in exposure predictions (including metabolites)
2. Determine whether tools give us enough biological coverage
3. Be explicit about the level of **confidence** in the assessment
4. Develop **agreed standards** for using tools and reporting data
5. Distinguish between adaptation and adversity
6. Develop an updated risk assessment workflow
7. **More case studies**

Regulatory Toxicology and Pharmacology 125 (2021) 105026



Contents lists available at [ScienceDirect](#)

Regulatory Toxicology and Pharmacology

journal homepage: [www.elsevier.com/locate/yrtph](http://www.elsevier.com/locate/yrtph)

ELSEVIER

Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients

M.P. Dent<sup>a,\*</sup>, E. Vaillancourt<sup>b</sup>, R.S. Thomas<sup>c</sup>, P.L. Carmichael<sup>a</sup>, G. Ouedraogo<sup>d</sup>, H. Kojima<sup>e</sup>, J. Barroso<sup>f</sup>, J. Ansell<sup>g</sup>, T.S. Barton-Maclaren<sup>b</sup>, S.H. Bennekou<sup>h</sup>, K. Boekelheide<sup>i</sup>, J. Ezendam<sup>j</sup>, J. Field<sup>b</sup>, S. Fitzpatrick<sup>k</sup>, M. Hatao<sup>l</sup>, R. Kreiling<sup>m</sup>, M. Lorencini<sup>n,1</sup>, C. Mahony<sup>o</sup>, B. Montemayor<sup>p</sup>, R. Mazaro-Costa<sup>q</sup>, J. Oliveira<sup>r</sup>, V. Rogiers<sup>s</sup>, D. Smegal<sup>k</sup>, R. Taalman<sup>t</sup>, Y. Tokura<sup>u</sup>, R. Verma<sup>k</sup>, C. Willett<sup>v</sup>, C. Yang<sup>w</sup>



# Identifying Best Practice from Case Studies

The Joint Working Group identified examples of NGRA in the literature, and used these to identify best practice of the application of the ICCR principles

“Highlighting best practices to advance NGRA of cosmetic ingredients”

[Vaillancourt et. al., 2025](#)



The collage consists of three overlapping documents:

- Top Document (US EPA Memorandum):** A memorandum from the United States Environmental Protection Agency. The subject is "Chlorothalopate Review". The date is 09-APR-2022. The author is George F. Kraus.
- Middle Document (Elsevier Article):** A scientific article titled "Next generation points-of-departure kinetic (PBK) metrics considered". Authors include Hequn Li, Haitao Yu, and Jiabin Guo.
- Bottom Document (Toxicology in Vitro Journal Article):** A journal article titled "Exploring *in vitro* to *in vivo* extrapolation for exposure and health impacts of e-cigarette flavor mixtures". Authors include Xiaoqing Chang, Jaleh Abedini, Shannon Bell, and K. Monica Lee.

# 1

## “Human Relevance”

Document the relevance of the hypothesis/hypotheses

Identify relevant exposures

Identify human-relevant test systems.

Identify assays/ biomarkers relevant to the hypothesis

# 2

## “Exposure-led”

External vs internal exposure

Exposure refinement

# 3

## “Hypothesis Driven”

Hypothesis may be highly specific or generic

Clearly articulate the hypothesis and sub-hypotheses so that the reader can transparently follow

## Overarching safety assessment hypothesis:

The use of x % of propylparaben in leave-on or rinse-off cosmetics does not induce skin sensitization.

### *Sub-hypothesis*

Based on their highly similar chemical structure, the target chemical propylparaben has similar bioavailability and bioactivity as the source chemicals methylparaben, ethylparaben and butylparaben.


In this assessment, the read-across hypothesis was followed by a step-by-step breakdown of the considerations that underpin the hypothesis (or further sub-hypotheses), including chemical structure, available *in vivo* data, quantitative and qualitative metabolism, and potency trend

## Overarching safety assessment hypothesis:


The use of x % of propylparaben in leave-on or rinse-off cosmetics does not induce skin sensitization.

### *Sub-hypothesis*

The similar chemical structure and physicochemical characteristics result in similar bioavailability, metabolism and reactivity which then result in similar biological and functional effects.



Proper articulation of the hypotheses provides clarity of the structure of the assessment and the lines of evidence needed to make a conclusion, demonstrating the suitability of the NAMs selected to test the hypotheses




# Digging Deeper

- Best practices reflecting application of the ICCR Principles had been identified and highlighted
- The next level of best practice still needed by risk assessors to help practical application of NAMs and safety assessment workflows
- →International Collaboration on Cosmetics Safety

# ICCS Best Practice

Not to be confused with ICCR, ICCS is a global, not-for-profit organization with members from cosmetic manufacturers, ingredient manufacturers, NGOs, and trade associations.

ICCS draws on world-leading expertise of its members to develop best practice guidance documents that support the use of NAMs




# ICCS Best Practice


A unique resource, providing exposure-led, tiered workflows in accordance with the ICCR Principles

Best Practices being developed for:

- Skin and eye irritation
- Exposure-based waiving
- Read across
- Others...



# Back to the ICCR: Ottawa 2025



1

Case studies have shown the value of the ICCR Principles of NGRA

---

2

Case studies can be used to highlight best practice

---

3

It's time to move beyond case studies to applying NGRA for real world safety decisions